HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine

Updated subgroup efficacy and quality of life data were also presented on June 1 at ASCO 2024HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 03, 2024 -- HUTCHMED Limited today announces that...

Related Keywords

Australia ,China ,Shanghai ,Japan ,Macau ,Hong Kong ,Panmure ,Victoria ,United States ,American ,Freddy Crossley ,Daphne Zhang ,Eli Lilly ,Ben Atwell Alex Shaw ,Atholl Tweedie ,Zhou Yi ,Stock Exchange Of Hong Kong ,China National Reimbursement Drug List ,China Limited ,World Health Organization ,American Society Of Clinical Oncology ,Linkedin ,Nasdaq ,Journal Of The American Medical Association ,Exchange Commission ,American Society ,Clinical Oncology ,Nature Medicine ,About Gastric ,Fruquintinib Approval ,American Medical Association ,Prescribing Information ,Securities Litigation Reform Act ,Stock Exchange ,Alex Shaw ,Global Cancer Observatory ,Stomach Cancer Fact ,Accessed April ,China Fact ,